Zoetis Inc. (NYSE:ZTS) Receives $109.62 Average PT from Brokerages

Zoetis Inc. (NYSE:ZTS) has been assigned an average rating of “Hold” from the nineteen research firms that are currently covering the company, Marketbeat.com reports. Two equities research analysts have rated the stock with a sell recommendation, nine have assigned a hold recommendation and eight have given a buy recommendation to the company. The average 1-year target price among brokerages that have issued a report on the stock in the last year is $109.6154.

Several brokerages have issued reports on ZTS. TD Cowen lowered their target price on shares of Zoetis from $150.00 to $104.00 and set a “buy” rating on the stock in a research note on Tuesday, June 30th. Argus reaffirmed a “hold” rating on shares of Zoetis in a research note on Wednesday, May 27th. Wall Street Zen lowered shares of Zoetis from a “buy” rating to a “hold” rating in a research note on Saturday, May 2nd. JPMorgan Chase & Co. dropped their price target on Zoetis from $130.00 to $115.00 and set an “overweight” rating for the company in a research report on Friday, August 7th. Finally, Zacks Research cut Zoetis from a “hold” rating to a “strong sell” rating in a report on Monday, August 10th.

Zoetis Stock Up 1.5%

ZTS stock opened at $74.04 on Wednesday. Zoetis has a 52 week low of $71.00 and a 52 week high of $160.48. The company has a quick ratio of 1.84, a current ratio of 3.08 and a debt-to-equity ratio of 2.87. The firm has a 50-day simple moving average of $76.01 and a 200-day simple moving average of $98.13. The stock has a market capitalization of $30.60 billion, a P/E ratio of 12.20, a P/E/G ratio of 1.28 and a beta of 0.73.

Zoetis (NYSE:ZTS) last posted its quarterly earnings data on Thursday, August 6th. The company reported $1.87 earnings per share (EPS) for the quarter, topping the consensus estimate of $1.85 by $0.02. The company had revenue of $2.47 billion for the quarter, compared to analysts’ expectations of $2.50 billion. Zoetis had a return on equity of 74.89% and a net margin of 27.49%.Zoetis’s revenue was down .2% compared to the same quarter last year. During the same period in the previous year, the firm posted $1.76 EPS. Zoetis has set its FY 2026 guidance at 6.150-6.250 EPS. Equities analysts forecast that Zoetis will post 6.2 earnings per share for the current fiscal year.

Institutional Investors Weigh In On Zoetis

A number of hedge funds have recently modified their holdings of the company. Livforsakringsbolaget Skandia Omsesidigt acquired a new stake in Zoetis during the second quarter worth about $182,000. Dearborn Partners LLC acquired a new position in Zoetis in the 2nd quarter valued at about $1,724,000. Public Employees Retirement System of Ohio acquired a new position in Zoetis in the 2nd quarter valued at about $9,138,000. Ancora Advisors LLC purchased a new stake in shares of Zoetis in the 2nd quarter valued at approximately $2,642,000. Finally, Jones Financial Companies Lllp purchased a new stake in shares of Zoetis in the 2nd quarter valued at approximately $1,877,000. Hedge funds and other institutional investors own 92.80% of the company’s stock.

About Zoetis

Zoetis Inc (NYSE: ZTS) is a global animal health company that develops, manufactures and markets a broad portfolio of products and services for companion animals and livestock. The company’s offerings include pharmaceuticals, vaccines and biologics, parasiticides and anti-infectives, as well as diagnostic instruments, consumables and laboratory testing services. Zoetis serves the veterinary community, livestock producers and other animal-health customers with products designed to prevent, detect and treat disease and to support animal productivity and welfare.

Zoetis traces its roots to the animal health business of Pfizer and became an independent, publicly traded company following a 2013 separation and initial public offering.